Litigation Details for Acorda Therapeutics Inc. v. Aurobindo Pharma Ltd. (D. Del. 2014)

Acorda Therapeutics Inc. v. Aurobindo Pharma Ltd. (D. Del. 2014)

Docket		Date Filed	2014-07-10
Court	District Court, D. Delaware	Date Terminated	2015-12-15
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,007,826; 8,354,437; 8,440,703; 8,663,685
Link to Docket	External link to docket

Details for Acorda Therapeutics Inc. v. Aurobindo Pharma Ltd. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-10				External link to document

Acorda Therapeutics v. Aurobindo Pharma: Litigation Summary, Ampyra Patent Analysis, and Generic Entry Risk

Last updated: August 20, 2026

Acorda Therapeutics Inc. v. Aurobindo Pharma Ltd., No. 1:14-cv-00909, was part of Acorda's Hatch-Waxman litigation against generic applicants seeking approval for dalfampridine extended-release tablets, marketed as Ampyra. The dispute centered on U.S. Patent Nos. 5,540,938 and 8,007,826, which covered methods of treating multiple sclerosis symptoms with sustained-release 4-aminopyridine formulations.

Acorda initially prevailed in the District of Delaware, where the asserted claims were upheld against obviousness challenges. The Federal Circuit later reversed, holding the asserted claims obvious. That appellate ruling materially weakened the principal Ampyra patent estate and removed the primary patent barrier to ANDA approval and generic entry. The case is reported with the related Ampyra litigation, including Acorda Therapeutics Inc. v. Roxane Laboratories Inc., 903 F.3d 1310 (Fed. Cir. 2018).

What drug and patents were at issue in Acorda v. Aurobindo?

The litigation concerned Ampyra, a 10-mg extended-release dalfampridine tablet approved by the FDA to improve walking in adults with multiple sclerosis.

Item	Detail
Brand	Ampyra
Active ingredient	Dalfampridine, also known as 4-aminopyridine
Dosage form	Extended-release tablet
Strength	10 mg
FDA approval	Jan. 22, 2010
NDA	022250
NDA holder	Acorda Therapeutics
Generic pathway	Abbreviated New Drug Application
Primary patents litigated	U.S. Patent Nos. 5,540,938 and 8,007,826
Court	U.S. District Court for the District of Delaware
Case number	1:14-cv-00909
Federal Circuit authority	903 F.3d 1310

The asserted patents addressed two related aspects of dalfampridine therapy:

1. The use of a sustained-release formulation of 4-aminopyridine to improve walking ability in multiple sclerosis patients.
2. Pharmacokinetic and dosage limitations intended to provide therapeutic exposure while reducing seizure risk associated with higher dalfampridine concentrations.

The case did not involve a biologic product. Biosimilar standards under the Public Health Service Act were not relevant. Aurobindo's challenge proceeded through the ANDA and Hatch-Waxman framework applicable to small-molecule drugs.

What patents protected Ampyra in the Aurobindo litigation?

The principal asserted patents were U.S. Patent Nos. 5,540,938 and 8,007,826.

U.S. Patent No. 5,540,938

The '938 patent covered methods involving sustained-release 4-aminopyridine for treating patients with multiple sclerosis. Its claims focused on administering the active ingredient in a controlled-release form to improve neurological function, including walking ability.

Acorda relied on the '938 patent as a method-of-use patent. The patent was important because a generic applicant could be exposed to infringement liability through a Paragraph IV certification even if the generic label did not expressly promote every patented use. The scope of induced infringement depended on the proposed labeling, prescribing information, and the relationship between the claimed use and the approved indication.

U.S. Patent No. 8,007,826

The '826 patent covered sustained-release dalfampridine formulations and related pharmacokinetic parameters. Acorda relied on this patent as a formulation and product patent.

The patent's commercial relevance came from its connection to the Ampyra extended-release dosage form. The formulation allowed twice-daily administration and was designed to avoid the rapid concentration increases associated with immediate-release 4-aminopyridine.

Later Ampyra-related patents

Acorda also obtained later patents relating to dalfampridine formulations, dosing, and manufacturing. Those patents were separate from the core claims adjudicated in the Aurobindo and related 2014 cases. Their existence did not restore the validity of the '938 and '826 claims after the Federal Circuit's obviousness ruling.

What was Aurobindo's Paragraph IV challenge?

Aurobindo filed an ANDA seeking approval to market generic dalfampridine extended-release tablets. Its Paragraph IV certification asserted that the relevant Ampyra patents were invalid, unenforceable, or would not be infringed.

Acorda responded by filing the Delaware action. The filing triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to earlier termination through court judgment or other statutory events.

Aurobindo's principal defense was obviousness. The generic defendants argued that the claimed sustained-release dalfampridine treatment was an obvious application of known 4-aminopyridine pharmacology and prior-art controlled-release technology.

The central question was whether the prior art would have led a skilled person to develop the claimed formulation and dosage regimen with a reasonable expectation of success, while accounting for the known seizure and toxicity concerns associated with 4-aminopyridine.

How did the District of Delaware decide the Ampyra patent case?

The District of Delaware initially found the asserted claims not invalid for obviousness. The court accepted Acorda's evidence that the prior art did not provide a sufficient reason to select the claimed dosage and release profile, particularly because of safety concerns and uncertainty regarding the therapeutic window.

The district court also credited evidence of commercial success and other secondary considerations. Ampyra's commercial performance was relevant because the product achieved market adoption despite the technical and safety challenges associated with 4-aminopyridine.

The district court's ruling preserved the asserted claims against the generic defendants at the trial stage. The decision did not end the litigation because the defendants pursued appellate review.

Why did the Federal Circuit invalidate the Ampyra patent claims?

The Federal Circuit reversed the district court in 2018 and held the asserted claims obvious. The court focused on the known properties of 4-aminopyridine, the prior art's disclosure of sustained-release formulations, and the incentives to address peak-concentration safety problems.

The Federal Circuit rejected the district court's treatment of the prior art as teaching away from the claimed invention. It concluded that the prior art provided a reason to pursue sustained-release delivery and that the claimed formulation was within the range of predictable options available to a skilled artisan.

The court also found that Acorda's evidence of commercial success did not overcome the strong prima facie showing of obviousness. The opinion emphasized that commercial success must have a sufficient nexus to the claimed features. Acorda's market position reflected both the patented technology and factors such as regulatory approval, physician adoption, and the absence of competition.

The Federal Circuit's decision is significant because it treated the patent claims as an incremental formulation and dosing advance rather than a nonobvious breakthrough. The ruling affected the related Aurobindo litigation because the same core patent claims and obviousness issues were litigated across multiple generic defendants.

What was the final litigation impact for Aurobindo?

The Federal Circuit's decision eliminated the principal merits-based obstacle to Aurobindo's ANDA for generic dalfampridine. The asserted '938 and '826 claims could no longer provide a reliable basis for keeping Aurobindo's product off the market through the 2014 litigation.

The result was more important than a routine claim-construction dispute. The appellate judgment reached the validity of the key patents themselves. Once those claims were held obvious, Acorda could not rely on them to obtain a conventional patent injunction against Aurobindo.

The related judgments also reduced the leverage available for settlements with other generic applicants. Acorda's commercial position thereafter depended more heavily on later-issued patents, regulatory exclusivity, product differentiation, and any negotiated launch arrangements.

What is the Orange Book status of Ampyra?

Ampyra was listed in the FDA Orange Book as an NDA drug with patent information submitted by the NDA holder. Orange Book-listed patents can support a Paragraph IV suit and a 30-month stay, but Orange Book listing does not establish patent validity.

The '938 and '826 patents were the primary Orange Book-linked patents relevant to the 2014 ANDA cases. Their litigation history demonstrates the difference between listing status and enforceable exclusivity:

Issue	Practical effect
Orange Book listing	Permits patent certification and can trigger Hatch-Waxman litigation
Paragraph IV certification	Creates a statutory basis for suit
30-month stay	Delays FDA approval unless shortened or otherwise terminated
District court validity ruling	Can preserve the patent initially
Federal Circuit reversal	Removes the patent's operative litigation barrier
Patent expiry	Ends ordinary patent-based exclusion regardless of listing

The Orange Book remained relevant to later generic approvals and any later patent certifications, but the Federal Circuit's ruling substantially changed the risk profile for the core patents.

When did Ampyra lose exclusivity?

Ampyra's effective market exclusivity depended on several separate rights:

1. FDA regulatory exclusivity.
2. Patent exclusivity under the listed patents.
3. Any patent term extension or adjustment.
4. Later patents covering formulation, dosing, or manufacturing.
5. Settlement-based launch dates.

The FDA approved Ampyra in January 2010. New chemical entity exclusivity for the active ingredient provided an initial period during which ANDA approval was restricted. That regulatory period was distinct from patent protection.

The practical loss of core patent protection occurred when the Federal Circuit held the asserted '938 and '826 claims obvious in 2018. Formal patent expiration dates remained relevant to the record, but invalidity removed the claims as an effective exclusionary right against the litigated ANDAs.

How strong was Acorda's Ampyra patent estate?

The estate was commercially valuable but vulnerable to an obviousness attack.

Strengths

Acorda had several favorable characteristics:

• A marketed product with meaningful multiple sclerosis revenue.
• A clinically useful extended-release dosage form.
• Regulatory approval supporting a nexus between the claimed treatment and commercial demand.
• Multiple patents directed to use, formulation, and pharmacokinetic features.
• A safety rationale for controlling dalfampridine exposure.

Weaknesses

The principal weaknesses were:

• The active compound, 4-aminopyridine, was known.
• Sustained-release drug delivery was a familiar pharmaceutical technique.
• The claims were relatively narrow combinations of known pharmacology and formulation principles.
• Commercial success did not establish that the claimed features, rather than regulatory or market factors, drove sales.
• The Federal Circuit viewed the path to the claimed formulation as predictable.

Patent-estate factor	Assessment
Composition-of-matter protection	Limited for dalfampridine because the active ingredient was known
Formulation protection	Material but exposed to obviousness arguments
Method-of-use protection	Valuable commercially but vulnerable to prior-art combinations
Manufacturing protection	Potentially useful for later lifecycle management
Regulatory exclusivity	Temporary and separate from patent validity
Litigation strength after 2018	Substantially reduced for the core patents

What generic entry risks existed after the Federal Circuit ruling?

The ruling created a high probability of generic entry once FDA approval and applicant-specific regulatory requirements were satisfied. The principal risks were no longer centered on the validity of the '938 and '826 patents.

The remaining commercial risks included:

• Later-issued formulation or manufacturing patents.
• Applicant-specific infringement claims under other listed patents.
• FDA approval timing.
• Paragraph IV litigation involving later patents.
• Labeling restrictions and skinny-label strategy.
• State substitution rules and pharmacy adoption.
• Product quality, supply, and manufacturing readiness.

Aurobindo's product would compete primarily on price and payer access. Ampyra's brand retention would depend on prescribing familiarity, reimbursement, patient switching costs, and any authorized-generic or settlement strategy.

Did biosimilar risk apply to Ampyra?

No. Ampyra is a small-molecule drug, not a biologic. The relevant competitive pathway was an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The appropriate market-entry risks were generic substitution, Paragraph IV litigation, patent listing disputes, and formulation or method-of-use enforcement. Biosimilar interchangeability and the Biologics Price Competition and Innovation Act were not part of the Aurobindo dispute.

What litigation and settlement issues affected Ampyra competitors?

Acorda filed related patent cases against several ANDA applicants, including Aurobindo and Roxane. The cases were coordinated around the same core Ampyra patents and raised substantially overlapping obviousness questions.

The Federal Circuit's 2018 decision changed the settlement environment. Before the decision, Acorda could negotiate from the position of a district court victory and an active injunction risk. After the decision, generic applicants had materially greater leverage because the core patents could not reliably block approval.

Settlement terms in pharmaceutical patent cases can include:

• A permitted generic launch date.
• A license to later patents.
• Restrictions tied to FDA approval.
• Authorized-generic arrangements.
• Supply or co-promotion provisions.
• Releases covering specified patents and products.

The appellate decision itself did not create a universal launch date for every applicant. Each applicant remained subject to its own ANDA status, applicable patents, regulatory approval, and any separate agreement.

How did Acorda v. Aurobindo compare with other Ampyra cases?

Litigation feature	Acorda v. Aurobindo	Related Ampyra cases
Product	Generic dalfampridine ER	Generic dalfampridine ER
Core patents	'938 and '826	'938 and '826
Court	District of Delaware	District of Delaware
Main defense	Obviousness	Obviousness
District court result	Core claims initially upheld	Similar trial-level outcome
Federal Circuit result	Controlled by 903 F.3d 1310	Asserted claims held obvious
Market effect	Reduced barrier to Aurobindo entry	Reduced barrier across generic applicants

The cases should be analyzed together for validity and patent-strength purposes, but an applicant's final commercial launch position still depended on its individual ANDA, settlement terms, and later patent coverage.

What revenue exposure did the litigation create for Acorda?

Ampyra was Acorda's principal commercial product, making generic entry a concentrated revenue risk. The litigation threatened the product's price, volume, and net revenue rather than merely a single indication.

Generic entry typically affects branded products through:

• Rapid price erosion.
• Formulary substitution.
• Reduced refill retention.
• Payer-mandated generic use.
• Lower physician willingness to initiate branded therapy.
• Declining sales before complete market conversion.

Acorda's ability to offset the loss depended on later-stage pipeline products, licensing, cost controls, and any lifecycle-management patents that survived separate challenges. The 2018 invalidity ruling materially increased the urgency of those strategies.

Key Takeaways

• Acorda sued Aurobindo in the District of Delaware over an ANDA for generic Ampyra, or dalfampridine extended-release tablets.
• The primary patents were U.S. Patent Nos. 5,540,938 and 8,007,826.
• The district court initially upheld the asserted claims against obviousness challenges.
• The Federal Circuit reversed in 2018 and held the asserted claims obvious.
• The decision removed the core patent barrier to Aurobindo's generic entry.
• Ampyra was subject to small-molecule generic competition, not biosimilar competition.
• Later patents and applicant-specific regulatory issues remained relevant after the core patents were invalidated.
• The litigation created substantial revenue and pricing exposure because Ampyra was Acorda's principal commercial product.

FAQs About Acorda v. Aurobindo and Ampyra Patent Litigation

What was Aurobindo's proposed generic product?

Aurobindo sought approval for generic dalfampridine extended-release tablets equivalent to Ampyra 10 mg.

Did Acorda win the Ampyra patent litigation?

Acorda won initially in the District of Delaware, but the Federal Circuit reversed and held the asserted claims obvious. The appellate decision controlled the principal validity dispute.

Were the Ampyra patents composition-of-matter patents?

No. The core patents primarily covered sustained-release formulations, dosing parameters, and methods of treating multiple sclerosis symptoms with dalfampridine.

Could Acorda sue Aurobindo over later Ampyra patents?

Yes. A later patent could support a separate infringement action if it was properly listed, certified against, and applicable to Aurobindo's ANDA product. The 2018 decision did not automatically invalidate every later Acorda patent.

What regulatory pathway applied to Aurobindo?

Aurobindo proceeded under the ANDA pathway for a generic small-molecule drug. The relevant statutory framework was the Hatch-Waxman Act, including Paragraph IV certification and the potential 30-month FDA approval stay.

References

1. Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., 903 F.3d 1310 (Fed. Cir. 2018).

2. Acorda Therapeutics, Inc. v. Aurobindo Pharma Ltd., No. 1:14-cv-00909, U.S. District Court for the District of Delaware.

3. U.S. Food and Drug Administration. (2010). Ampyra (dalfampridine) extended-release tablets, NDA 022250: Approval letter and prescribing information.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

5. United States Patent and Trademark Office. (1996). U.S. Patent No. 5,540,938: Sustained release formulation of 4-aminopyridine.

6. United States Patent and Trademark Office. (2011). U.S. Patent No. 8,007,826: Sustained release aminopyridine composition.